

## Heptaplatin

## Chemical Properties


CAS No. : 146665-77-2

Formula: C<sub>11</sub>H<sub>20</sub>N<sub>2</sub>O<sub>6</sub>Pt

Molecular Weight: 471.36

Storage:

Keep away from direct sunlight, The compound is unstable in solution. Please use soon  
 Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Heptaplatin, a new platinum derivative with anticancer activity, is used against various cancer cell lines, including cisplatin-resistant cancer cell lines. It has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer.
Targets(IC50)	Others, DNA Alkylator/Crosslinker

## Solubility Information

Solubility	DMSO: Soluble, DMSO inactivates the activity of Heptaplatin. H <sub>2</sub> O: Insoluble, ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
------------	--

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1215 mL	10.6076 mL	21.2152 mL
5 mM	0.4243 mL	2.1215 mL	4.243 mL
10 mM	0.2122 mL	1.0608 mL	2.1215 mL
50 mM	0.0424 mL	0.2122 mL	0.4243 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Liu W, Chen X, Ye Q, Xu Y, Xie C, Xie M, Chang Q, Lou L. A novel water-soluble heptaplatin analogue with improved antitumor activity and reduced toxicity. *Inorg Chem*. 2011 Jun 20;50(12):5324-6. doi: 10.1021/ic200436u. Epub 2011 May 20. PubMed PMID: 21598993.

Al-Anazi KM, Abou-Tarboush FM, Abdel-Samad MF, Farah MA, Al-Faifi MY, Al-Ahmadi BA. Embryo-feto-toxicity of anticancer drug, heptaplatin in laboratory mice. *Pak J Biol Sci*. 2010 Sep 15;13(18):896-900. PubMed PMID: 23350163.

Lee KH, Hyun MS, Kim HK, Jin HM, Yang J, Song HS, Do YR, Ryoo HM, Chung JS, Zang DY, Lim HY, Jin JY, Yim CY, Park HS, Kim JS, Sohn CH, Lee SN. Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. *Cancer Res Treat*. 2009 Mar;41(1):12-8. doi: 10.4143/crt.2009.41.1.12. Epub 2009 Mar 31. PubMed PMID: 19688066; PubMed Central PMCID: PMC2699097.

Lee JW, Park JK, Lee SH, Kim SY, Cho YB, Kuh HJ. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. *Anticancer Drugs*. 2006 Apr;17(4):377-84. PubMed PMID: 16549994.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481